Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections in both the vagina and rectum in animals: HIV, herpes simplex virus 2, and human papillomavirus.

Published
22 April 2014
From
Eurekalert Medicine & Health
HIV incidence is high among pregnant and postpartum women and increases the risk of mother-to-child transmission

HIV incidence is high among pregnant and postpartum women and is associated with an increased risk of mother-to-child transmission (MTCT) of HIV, results of a systematic review and

Published
25 March 2014
By
Michael Carter
Dapivirine vaginal ring safe and effective in tissue study, but maraviroc component doesn't work

Vaginal rings containing the experimental NNRTI dapivirine were well tolerated and blocked HIV infection of cervical tissue samples, but rings containing maraviroc did not produce adequate drug concentrations,

Published
20 March 2014
By
Liz Highleyman
Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job

The National Institutes of Health has shown that a study of its vaginal ring for the prevention of HIV came back with mixed results. The ring, which delivers two drugs, was safe for 28 days, but only one of the antiretroviral drugs was effective in protecting against the virus.

Published
10 March 2014
From
Fierce Drug Delivery
New Rings, Gels, and Films Show Promise in Microbicide Trials

Experimental vaginal microbicides—products such as gels, films, or flexible rings worn inside the vagina—were the focus of two studies reported Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections.

Published
05 March 2014
From
BETA blog
Study comparing injectable contraceptives DMPA and NET-EN finds HIV risk higher with DMPA

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE. The new analysis, conducted by researchers from the NIH-funded Microbicide Trials Network, is the first head-to-head observational study to directly compare differences in HIV risk between users of DMPA and NET-EN.

Published
04 March 2014
From
Eurekalert Medicine & Health
Janssen Announces New Group Targeting Unmet Global Health Needs

Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets, and includes bedaquiline for drug-resistant TB, long-lasting injectable rilpivirine for HIV prevention and the dapivirin ring for HIV prevention.

Published
22 January 2014
From
Janssen press release
USAID, Population Council agreement for non-antiretroviral microbicide quest looks to expand prevention toolbox

An agreement between the United States Agency for International Development and the Population Council announced Monday for the development of a non-antiretroviral-based compound to block HIV and other sexually transmitted infections could yield a low-risk, easy access product for women in low resource settings in as few as a dozen years, if a promising new compound performs as hoped. That is a big if - the field of microbicide research has seen a roller coaster of raised expectations and dashed hopes over the last decades.

Published
11 January 2014
From
Science Speaks
AAPS showcases vaginal ring with tenofovir + contraceptive, gel suitable for vaginal and rectal use

A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.

Published
21 November 2013
From
HIVandHepatitis.com
Novel microbicide gel for vagina and rectum shows potential for HIV prevention

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus. The DuoGel will deliver ImQuest's antiretroviral compound IQP-0528.

Published
15 November 2013
From
Eurekalert Inf Dis
← First12345...17Next →

Filter by country